Innovation Ventures

Contact Us
☰
  • Partnering Opportunities
  • Partners
  • Investors
  • Innovators
  • About
  • Subscribe
  • facebookyoutubetwitterpinterest

Refine by

Category
Technology Type
Area of Interest
Stage of Development
Patent Status

Partnering Opportunities


  • Behavioral Medicine & Nephrology

    Digitally-Enabled Adherence Platform (DEAP)

    A software platform to monitor and improve patients' adherence to medications and treatments.

  • Infection treatment and prevention (pre / probiotic)

    Microbiota-derived retinoid boosts immunity

    Probiotic bacteria strains increase infection resistance.

  • Gastroenterology

    Biomarker Response Signatures of Children Receiving Infliximab for Crohn’s Disease

    Plasma Proteomic Response Signature of Children Receiving Infliximab for Crohn’s Disease

  • Drug Delivery

    Morcellator for use with Feeding Tubes

    A prototype of a self-contained morcellator for preparing medication for feeding tube delivery

  • Dermatology

    Thrombin Inhibitor as Novel Oral Treatment for Atopic Dermatitis

    A newly established link between the mechanistic role of thrombin and fibrinogen and their contribution to AD provides a novel mechanism for oral treatment.

  • Drug Discovery and Development

    Comprehensive Method to Package mRNA Gene Therapies, Vaccines and Protein Replacement Therapies

    Comprehensive method to package mRNA gene therapies, vaccines and protein replacement therapies

  • Gastroenterology

    Elevated Oncostatin M Predicts Non-response to Anti-TNF Therapy

    Oncostatin M biomarkers are associated with non-response to Infliximab therapy

  • Genetic Diseases

    Novel Treatment to Ensure Efficacious Dosage for Multiple, Rare Genetic Diseases

    Optimal dosing regimen for treating seizures and self-aggressive behavior

  • Drug Discovery and Development

    Polymer-based product streamlines population cell analysis

    Single cell labeling method to aid in applied medicine and drug development

  • Oncology

    Novel Small Molecule RAC-Pathway Inhibitor for the Treatment of Cancer

    Our proprietary inhibitor binds to VAV3 thereby inhibiting the activation of RAC downstream of several oncogenes.

Next Page

Cincinnati Children’s Innovation Ventures

3333 Burnet Avenue, MLC 7032 Cincinnati, Ohio 45229-3026 | partnering@cchmc.org

© 1999-2023 Cincinnati Children's Hospital Medical Center